Loading clinical trials...

NOT_YET_RECRUITINGPHASE2

Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion

A Prospective Phase II Clinical Study of Carbon Ion Re-irradiation in Unresectable Locally Recurrent Rectal Cancer

NCT05807984•Xin Cai

Summary

Prospective phase II clinical study aim to explore the clinical outcome of patients with unresectable locally recurrent rectal cancer (LRRC) treated with re-irradiation by carbon ion radiotherapy (CIRT)

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1\) pathologically confirmed rectal adenocarcinoma (including mucinous adenocarcinoma and signet-ring cell carcinoma) and LRRC confirmed by biopsy or clinical diagnosis,
•2\) received a radical operation for their primary tumor and regional lymph nodes,
•3\) received chemo-radiation or radiation in pelvic before CIRT,
•4\) received re-irradiation by CIRT after their pelvic radiotherapy.

Exclusion Criteria

•1\) received more than once prior radiotherapy in the same treatment field,
•2\) time to the last radiotherapy was \<1 year,
•3\) space between the lesion to organ at risk (OARs) (bladder or digestive tract) was too close (\<5 mm).

Locations (1)

Shanghai Proton and Heavy ion center

Shanghai, Pudong, China

Key Dates

Start Date

May 1, 2023

Primary Completion Date

December 31, 2025

Completion Date

December 31, 2026

Last Updated

April 11, 2023

Enrollment

ESTIMATED participants

Conditions

Rectal CancerRecurrent

Interventions

Carbon ion radiation therapy DT: 74Gy/20 fractions

RADIATION

Contacts

Xin Cai, Doctor

CONTACT

+86 13901601072 xin.cai@sphic.org.cn

Zheng Wang, Doctor

CONTACT

+86 021-38296666 zheng.wang@sphic.org.cn

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

RECRUITINGPHASE2/PHASE3

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

NCT05058651

Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine Carcinoma+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 11, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion

Inclusion Criteria

Exclusion Criteria

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma